ACTRN12619001247167
Recruiting
未知
Prospective Clinical Drug-Drug Interaction study between Rifampicin and Fusidic Acid in the context of staphylococcal infection
St Vincent's Hospital Melbourne0 sites12 target enrollmentSeptember 10, 2019
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Medication interaction
- Sponsor
- St Vincent's Hospital Melbourne
- Enrollment
- 12
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inpatients with presumed or confirmed staphylococcal infection
- •\-A decision to treat with oral rifampicin and fusidic acid has already been made but not started.
- •\-Treatment with an intravenous beta\-lactam antibiotic
Exclusion Criteria
- •\-Previous adverse reaction to rifampicin or fusidic acid
- •\-Pregnancy
- •\-The taking of other essential medications with a known significant interaction with rifampicin and fusidic acid
- •\-Liver failure
- •\-Unlikely to receive antibiotic treatment for longer than 4 weeks
- •\-Primary intravenous treatment with vancomycin or teicoplanin
- •\-Already on treatment with intravenous rifampicin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Pharmacokinetic drug-drug interaction study between oral 300 mg netupitant/0.50 mg palonosetron fixed dose combination (Akynzeo®) and oral dexamethasone to evaluate the duration of the CYP3A4 inhibition in healthy subjectsInhibitory effect on CYP3A4Not ApplicableISRCTN93845260Helsinn Healthcare SA24
Completed
Not Applicable
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancerprostate cancer10036958NL-OMON44408Johnson & Johnson Pharmaceutical10
Completed
Phase 2
Clinical Pharmacology Study -Drug-Drug Interaction Study of CNT-01Idiopathic triglyceride deposit cardiomyovasculopathyJPRN-jRCT2031220678Akita Yasuhiko32
Completed
Not Applicable
Drug-drug interaction study to explore importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatihealthy male subjectsJPRN-UMIN000002477Clinical trial Center,Kitsato University East Hospital8
Completed
Phase 4
To study the nature,mechanism and common drug class involved in possible drug-drug interactions in emergency medicine department patients admitted for at least two days in emergency department wards.Health Condition 1: O- Medical and SurgicalCTRI/2020/01/022913Kempegowda Institute of Medical Sciences110